Publications by authors named "N Marrouche"
Introduction: Catheter ablation of persistent atrial fibrillation yields sub-optimal success rates partly due to the considerable heterogeneity within the patient population. Identifying distinct patient phenotypes based on post-ablation prognosis could improve patient selection for additional therapies and optimize treatment strategies.
Methods: We studied all patients who underwent catheter ablation of persistent atrial fibrillation in the DECAAF II trial.
Atrial Fibrillation in Heart Failure: Novel Insights, Challenges, and Treatment Opportunities.
Curr Heart Fail Rep
November 2024
Purpose Of Review: Atrial fibrillation and heart failure frequently co-exist. This review discusses the comorbidity of atrial fibrillation and heart failure, the bi-directional link between them, and the recent advances in the management of these co-existing diseases.
Recent Findings: Catheter ablation received a class 1 A recommendation for patients with AF and HF, after overwhelming evidence in heart failure with reduced ejection fraction and end-stage heart failure, while clinical trials are still lacking in patients with preserved ejection.
Aims: Timely referrals for transplantation and left ventricular assist device (LVAD) play a key role in favourable outcomes in patients with advanced heart failure (HF). Cardiovascular mortality, driven by sudden cardiac death, is the main reason for dying while waiting for heart transplantation (HTx). The purpose of the Preventive Catheter Ablation for ventricular arrhythmiaS in patients with end-sTage heart faiLure rEferred for heart transplantation eValuaTion (CASTLE-VT) trial is to test the hypothesis that prophylactic catheter ablation of arrhythmogenic ventricular scar tissue will reduce mortality, need for LVAD implantation, and urgent HTx in patients with end-stage HF related to ischaemic cardiomyopathy (ICM).
View Article and Find Full Text PDFArticle Synopsis
- * In a study of 194 patients, those who underwent catheter ablation showed a significant decrease in AF recurrence and improvement in their heart function, with left ventricular ejection fraction (LVEF) rising from 29.2% to 39.1% after 12 months.
- * Overall, AF ablation not only lowered AF burden but also successfully shifted patients from persistent AF to a less severe form, benefiting those with or without left atrial cardiomyopathy.